Who are DZP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zulresso, Onfi, Lusedra, Campral, Sonata, Suprane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dzp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DZP — Competitive Intelligence Brief

DZP (DZP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine. Area: Neurology, Psychiatry.

phase 3 Benzodiazepine GABA-A receptor Neurology, Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

DZP (DZP) — UCB Biopharma SRL. DZP is a benzodiazepine that enhances GABAergic neurotransmission by potentiating the effect of GABA at GABA-A receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DZP TARGET	DZP	UCB Biopharma SRL	phase 3	Benzodiazepine	GABA-A receptor
Zulresso	BREXANOLONE	Sage Therap	marketed	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator	GABA-A receptor alpha-1/beta-2/gamma-2	2019-01-01
Onfi	CLOBAZAM	Lundbeck Pharms Llc	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	2011-01-01
Lusedra	FOSPROPOFOL		marketed	fospropofol	GABA-A receptor	2008-01-01
Campral	ACAMPROSATE	Allergan/AbbVie	marketed	acamprosate	GABA-A receptor alpha-1/beta-3/gamma-2	2004-01-01
Sonata	ZALEPLON	Pfizer	marketed	gamma-Aminobutyric Acid A Receptor Agonist [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1999-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-09-05 — Onfi · 12403090 · Formulation · US
2039-09-05 — Onfi · 12290597 · Formulation · US
2040-01-31 — Onfi · 11541002 · Formulation · US

Sponsor landscape (Benzodiazepine class)

Hamad Medical Corporation · 3 drugs in this class
Lundbeck LLC · 2 drugs in this class
UCB Biopharma SRL · 2 drugs in this class
Universitaire Ziekenhuizen KU Leuven · 2 drugs in this class
Bausch Health · 1 drug in this class
Centro Medico Nacional La Raza, IMSS · 1 drug in this class
Assaf-Harofeh Medical Center · 1 drug in this class
Daegu Catholic University Medical Center · 1 drug in this class
B.P. Koirala Institute of Health Sciences · 1 drug in this class
Consorci Sanitari de l'Anoia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DZP — Competitive Intelligence Brief. https://druglandscape.com/ci/dzp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab